Cover Image
Market Research Report

Global Q Fever Market Research Report Forecast to 2023

Published by Market Research Future Product code 882304
Published Content info 105 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Q Fever Market Research Report Forecast to 2023
Published: June 30, 2019 Content info: 105 Pages
Description

Introduction

Q fever is a mild disease with flu-like symptoms. In Q fever, the infection is caused by the bacterium Coxiella burnetii. Many patients have no symptoms at all, while, in some cases, the infection could reoccur/resurface years later. Chronic Q fever may damage the heart, liver, brain, lungs, and could cause diabetes in some cases.

The major factors driving the growth of the market include rising prevalence of Q fever coupled with increasing Q fever hospitalization rates, rising worldwide cattle, sheep, and goat population, growth in risk factors of Q fever, and globally growing geriatric population.

The global Q fever market has been segmented on the basis of type, diagnosis, treatment, end user, and region.

The global Q fever market, by type, has been segmented into acute and chronic.

The global Q fever market, by diagnosis, has been segmented into serology tests and others.

The global Q fever market, by treatment, has been segmented into antibiotics and surgery.

The global Q fever market, by end user, has been segmented into patients, hospitals and clinics, and others.

The global Q fever market is expected to reach a market value of USD 9,850.65 million by 2023 from USD 6,249.68 million in 2017 and is expected to register a CAGR of 7.83% during the forecast period of 2018 to 2023. In 2017, Asia-Pacific held the highest share of the market at 44.9%, followed by the Middle East and Africa with a share of 25.4%.

Key Players

Merck KGaA, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Basilea Pharmaceutica Ltd, Sanofi S. A., Melinta Therapeutics, Inc., Bayer AG, Johnson & Johnson Services, Inc., Yashica Pharmaceuticals, and AtoxBio.

Study Objectives

  • To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the Q fever market
  • To provide insights into factors affecting the market growth
  • To analyze the global Q fever market based on various tools such as supply chain analysis and Porter's five force analysis
  • To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries
  • To provide country-level analysis of the market with respect to the current market size and future perspective
  • To provide country-level analysis of the market for segments by type, diagnosis, treatment, end user, and region
  • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Q fever market

Target Audience

  • Hospitals
  • Q fever Companies
  • Associations and Organizations

Key Findings

  • The global Q fever market is expected to reach USD 9,850.65 million by 2023 at a CAGR of 7.83% from 2018 to 2023
  • On the basis of type, the chronic segment accounted for the largest market share in 2017 and is expected to grow at a CAGR of 7.33% during the forecast period
  • On the basis of diagnosis, the serology tests segment accounted for the largest market share in 2017 and is expected to grow at a CAGR of 8.32% during the forecast period
  • On the basis of treatment, the antibiotics segment accounted for the largest market share in 2017 and is expected to grow at a CAGR of 7.32% during the forecast period
  • On the basis of end user, the patients segment accounted for the largest market share in 2017 and is expected to grow at a CAGR of 8.21% during the forecast period

Regional Analysis

  • Americas
    • North America
  • US
  • Canada
    • Latin America
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Republic of Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Oman
    • Kuwait
    • Qatar
    • Africa
    • Rest of the Middle East & Africa
Table of Contents

Table of Contents

1 Report prologue

2 Market Introduction

  • 2.1 Definition
  • 2.2 Scope of the Study
  • 2.3 Assumptions & Limitations
    • 2.3.1 Assumptions
    • 2.3.2 Limitations
  • 2.4 Market Structure

3 Research Methodology

  • 3.1 Research Process
  • 3.2 Primary Research
  • 3.3 Secondary Research
  • 3.4 Market Size Estimation
  • 3.5 Forecast Model

4 Market Dynamics

  • 4.1 Introduction
  • 4.2 Drivers
    • 4.2.1 Worldwide Rising Prevalence of Q fever Coupled with Increasing Q Fever Hospitalization Rates
    • 4.2.2 Rising Worldwide Cattle, Sheep, and Goat Population
    • 4.2.3 Growth in the Risk Factors of Q Fever
    • 4.2.4 Globally Growing Geriatric Population
  • 4.3 Restraints
    • 4.3.1 High Cost of Diagnostic Tests
    • 4.3.2 Lack of Awareness About Q Fever
  • 4.4 Opportunity
    • 4.4.1 Presence of Untapped Opportunities in the Asia-Pacific and African Regions
  • 4.5 Market Trends
  • 4.6 Macroeconomic Indicators

5 Market Factor Analysis

  • 5.1 Porter's Five Forces Model
    • 5.1.1 Bargaining Power of Suppliers
    • 5.1.2 Bargaining Power of Buyers
    • 5.1.3 Threat of New Entrants
    • 5.1.4 Threat of Substitutes
    • 5.1.5 Rivalry
  • 5.2 Supply Chain Analysis
    • 5.2.1 R&D and Development
    • 5.2.2 Manufacturing
    • 5.2.3 Distribution & Sales
    • 5.2.4 Post-Sales Monitoring
  • 5.3 Investment Feasibility Analysis
  • 5.4 Pricing Analysis

6 Global Q Fever Market, By Type

  • 6.1 Overview
  • 6.2 Acute
  • 6.3 Chronic

7 Global Q Fever Market, By Diagnosis

  • 7.1 Overview
  • 7.2 Serology Tests
  • 7.3 Others

8 Global Q Fever Market, By Treatment

  • 8.1 Overview
  • 8.2 Antibiotics
  • 8.3 Surgery

9 Global Q Fever Market, By End-User

  • 9.1 Overview
  • 9.2 Patients
  • 9.3 Hospitals
  • 9.4 Others

10 Global Q Fever Market, By Region

  • 10.1 Overview
  • 10.2 Americas
    • 10.2.1 North America
      • 10.2.1.1 US
      • 10.2.1.2 Canada
    • 10.2.2 Latin America
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 France
    • 10.3.3 UK
    • 10.3.4 Italy
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia-Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia-Pacific
  • 10.5 Middle East & Africa
    • 10.5.1 UAE
    • 10.5.2 Saudi Arabia
    • 10.5.3 Oman
    • 10.5.4 Kuwait
    • 10.5.5 Qatar
    • 10.5.6 Africa
    • 10.5.7 Rest of Middle East & Africa

11 Company Profile

  • 11.1 Merck KGaA
    • 11.1.1 Company Overview
    • 11.1.2 Financial Overview
    • 11.1.3 Products/Services Offered
    • 11.1.4 SWOT Analysis
    • 11.1.5 Key Developments
    • 11.1.6 Key Strategies
  • 11.2 Teva Pharmaceutical Industries Ltd
    • 11.2.1 Company Overview
    • 11.2.2 Financial Overview
    • 11.2.3 Products/Services Offered
    • 11.2.4 Key Developments
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Strategies
  • 11.3 Pfizer Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Financial Overview
    • 11.3.3 Products/Services Offered
    • 11.3.4 SWOT Analysis
    • 11.3.5 Key Developments
    • 11.3.6 Key Strategies
  • 11.4 Basilea Pharmaceutica Ltd
    • 11.4.1 Company Overview
    • 11.4.2 Financial Overview
    • 11.4.3 Products/Services Offered
    • 11.4.4 Key Developments
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Strategies
  • 11.5 Sanofi S. A.
    • 11.5.1 Company Overview
    • 11.5.2 Financial Overview
    • 11.5.3 Products/Services Offered
    • 11.5.4 SWOT Analysis
    • 11.5.5 Key Developments
    • 11.5.6 Key strategies
  • 11.6 Melinta Therapeutics, Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Financial Overview
    • 11.6.3 Products/Services Offered
    • 11.6.4 Key Developments
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Strategies
  • 11.7 Bayer AG
    • 11.7.1 Company Overview
    • 11.7.2 Financial Overview
    • 11.7.3 Products/Services Offered
    • 11.7.4 SWOT Analysis
    • 11.7.5 Key Developments
    • 11.7.6 Key Strategies
  • 11.8 Johnson & Johnson Services, Inc.
    • 11.8.1 Company Overview
    • 11.8.2 Financial Overview
    • 11.8.3 Products/Services Offered
    • 11.8.4 SWOT Analysis
    • 11.8.5 Key Developments
    • 11.8.6 Key Strategies
  • 11.9 Yashica Pharmaceuticals
    • 11.9.1 Company Overview
    • 11.9.2 Financial Overview
    • 11.9.3 Products/Services Offered
    • 11.9.4 Key Developments
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Strategies
  • 11.1 AtoxBio
    • 11.10.1 Company Overview
    • 11.10.2 Financial Overview
    • 11.10.3 Products/Services Offered
    • 11.10.4 Key Developments
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Strategies

12 Appendix

  • 12.1 Discussion Blue Print

List of Tables

  • TABLE 1 PRIMARY INTERVIEWS
  • TABLE 2 TREATMENT COST FOR THE Q FEVER
  • TABLE 3 GLOBAL Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 4 GLOBAL Q FEVER MARKET, FOR ACUTE BY REGION, 2015-2023 (USD THOUSAND)
  • TABLE 5 GLOBAL Q FEVER MARKET, FOR CHRONIC BY REGION, 2015-2023 (USD THOUSAND)
  • TABLE 6 GLOBAL Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 7 GLOBAL Q FEVER MARKET, FOR SEROLOGY TESTS BY REGION, 2015-2023 (USD THOUSAND)
  • TABLE 8 GLOBAL Q FEVER MARKET, FOR OTHERS BY REGION, 2015-2023 (USD THOUSAND)
  • TABLE 9 GLOBAL Q FEVER MARKET, FOR ANTIBIOTICS BY REGION, 2015-2023 (USD THOUSAND)
  • TABLE 10 GLOBAL Q FEVER MARKET, FOR SURGERY BY REGION, 2015-2023 (USD THOUSAND)
  • TABLE 11 GLOBAL Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 12 GLOBAL Q FEVER MARKET, FOR PATIENTS BY REGION, 2015-2023 (USD THOUSAND)
  • TABLE 13 GLOBAL Q FEVER MARKET, FOR HOSPITALS BY REGION, 2015-2023 (USD THOUSAND)
  • TABLE 14 GLOBAL Q FEVER MARKET, FOR OTHERS BY REGION, 2015-2023 (USD THOUSAND)
  • TABLE 15 GLOBAL Q FEVER MARKET, BY REGION, 2015-2023 (USD THOUSAND)
  • TABLE 16 AMERICAS: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 17 AMERICAS: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 18 AMERICAS: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 19 AMERICAS: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 20 NORTH AMERICA: Q FEVER MARKET, BY COUNTRY, 2015-2023 (USD THOUSAND)
  • TABLE 21 NORTH AMERICAS: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 22 NORTH AMERICAS: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 23 NORTH AMERICAS: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 24 NORTH AMERICAS: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 25 US: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 26 US: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 27 US: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 28 US: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 29 CANADA: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 30 CANADA: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 31 CANADA: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 32 CANADA: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 33 LATIN AMERICA: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 34 LATIN AMERICA: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 35 LATIN AMERICA: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 36 LATIN AMERICA: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 37 EUROPE: Q FEVER MARKET, BY COUNTRY, 2015-2023 (USD THOUSAND)
  • TABLE 38 EUROPE: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 39 EUROPE: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 40 EUROPE: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 41 EUROPE: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 42 GERMANY: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 43 GERMANY: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 44 GERMANY: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 45 GERMANY: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 46 FRANCE: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 47 FRANCE: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 48 FRANCE: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 49 FRANCE: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 50 UK: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 51 UK: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 52 UK: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 53 UK: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 54 ITALY: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 55 ITALY: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 56 ITALY: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 57 ITALY: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 58 SPAIN: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 59 SPAIN: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 60 SPAIN: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 61 SPAIN: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 62 REST OF EUROPE: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 63 REST OF EUROPE: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 64 REST OF EUROPE: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 65 REST OF EUROPE: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 66 ASIA-PACIFIC: Q FEVER MARKET, BY COUNTRY, 2015-2023 (USD THOUSAND)
  • TABLE 67 ASIA-PACIFIC: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 68 ASIA-PACIFIC: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 69 ASIA-PACIFIC: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 70 ASIA-PACIFIC: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 71 JAPAN: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 72 JAPAN: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 73 JAPAN: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 74 JAPAN: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 75 CHINA: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 76 CHINA: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 77 CHINA: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 78 CHINA: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 79 INDIA: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 80 INDIA: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 81 INDIA: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 82 INDIA: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 83 AUSTRALIA: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 84 AUSTRALIA: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 85 AUSTRALIA: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 86 AUSTRALIA: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 87 SOUTH KOREA: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 88 SOUTH KOREA: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 89 SOUTH KOREA: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 90 SOUTH KOREA: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 91 REST OF ASIA-PACIFIC: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 92 REST OF ASIA-PACIFIC: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 93 REST OF ASIA-PACIFIC: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 94 REST OF ASIA-PACIFIC: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 95 MIDDLE EAST & AFRICA: Q FEVER MARKET, BY COUNTRY, 2015-2023 (USD THOUSAND)
  • TABLE 96 MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 97 MIDDLE EAST & AFRICA: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 98 MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 99 MIDDLE EAST & AFRICA: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 100 UAE: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 101 UAE: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 102 UAE: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 103 UAE: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 104 SAUDI ARABIA: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 105 SAUDI ARABIA: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 106 SAUDI ARABIA: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 107 SAUDI ARABIA: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 108 OMAN: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 109 OMAN: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 110 OMAN: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 111 OMAN: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 112 KUWAIT: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 113 KUWAIT: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 114 KUWAIT: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 115 KUWAIT: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 116 QATAR: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 117 QATAR: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 118 QATAR: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 119 QATAR: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 120 AFRICA: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 121 AFRICA: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 122 AFRICA: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 123 AFRICA: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)
  • TABLE 124 REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TYPE, 2015-2023 (USD THOUSAND)
  • TABLE 125 REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY DIAGNOSIS, 2015-2023 (USD THOUSAND)
  • TABLE 126 REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • TABLE 127 REST OF MIDDLE EAST & AFRICA: Q FEVER MARKET, BY END USER, 2015-2023 (USD THOUSAND)

List of Figures

  • FIGURE 1 GLOBAL Q FEVER MARKET: MARKET STRUCTURE
  • FIGURE 2 RESEARCH PROCESS
  • FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH
  • FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL Q FEVER MARKET
  • FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL Q FEVER MARKET
  • FIGURE 6 SUPPLY CHAIN: GLOBAL Q FEVER MARKET
  • FIGURE 7 GLOBAL Q FEVER MARKET SHARE, BY TYPE, 2017 (%)
  • FIGURE 8 GLOBAL Q FEVER MARKET, BY TYPE, 2017 & 2023 (USD THOUSAND)
  • FIGURE 9 GLOBAL Q FEVER MARKET SHARE, BY DIAGNOSIS, 2017 (%)
  • FIGURE 10 GLOBAL Q FEVER MARKET, BY DIAGNOSIS, 2017 & 2023 (USD THOUSAND)
  • FIGURE 11 GLOBAL Q FEVER MARKET, BY TREATMENT, 2015-2023 (USD THOUSAND)
  • FIGURE 12 GLOBAL Q FEVER MARKET SHARE, BY TREATMENT, 2017 (%)
  • FIGURE 13 GLOBAL Q FEVER MARKET, BY TREATMENT, 2017 & 2023 (USD THOUSAND)
  • FIGURE 14 GLOBAL Q FEVER MARKET SHARE, BY END USER, 2017 (%)
  • FIGURE 15 GLOBAL Q FEVER MARKET, BY END USER, 2017 & 2023 (USD THOUSAND)
  • FIGURE 16 GLOBAL Q FEVER MARKET SHARE, BY REGION, 2017 (%)
  • FIGURE 17 AMERICAS: Q FEVER MARKET SHARE, BY REGION, 2017 (%)
  • FIGURE 18 NORTH AMERICA: Q FEVER MARKET SHARE, BY COUNTRY, 2017 (%)
  • FIGURE 19 EUROPE: Q FEVER MARKET SHARE, BY COUNTRY, 2017 (%)
  • FIGURE 20 ASIA-PACIFIC: Q FEVER MARKET SHARE, BY COUNTRY, 2017 (%)
  • FIGURE 21 MIDDLE EAST & AFRICA: Q FEVER MARKET SHARE, BY COUNTRY, 2017 (%)
Back to Top